• News
  • SAN DIEGO
  • BioTech

Regen BioPharma files FDA application for anemia drug

Regen BioPharma announced Tuesday the filing of an Investigational New Drug (IND) application with the Food and Drug Administration to initiate clinical trials assessing the company's HemaXellerate I stem cell drug in patients with drug-refractory aplastic anemia.

To continue reading, subscribe now
or
log in to your account
User Response
0 UserComments

Bio-Matrix Scientific Group

Company Website

1649 Dartmouth
Chula Vista, CA 91913

Company Trade Data

Stock Symbol Close
Change
Chg %Chg
Volume
52-Week
High Low
BMSN
0.00
  0.00  
+ 0.00%
33,113,348,000
0.01
0.00

Bio-Matrix Scientific Group Executive(s):

David Koos

  • Chief Executive Officer, President, Chairman

Similar Companies

NAICS - 325414 - Biological Product (except Diagnostic) Manufacturing
SIC - 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES
NAICS - 423450 - Medical, Dental, and Hospital Equipment and Supplies Merchant Wholesalers
SIC - 5047 - MEDICAL, DENTAL, AND HOSPITAL EQUIPMENT AND SUPPLIES
Subscribe Today!